Drug Type Small molecule drug |
Synonyms Mefuparib, CVL-218, CVL218 |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC17H16ClFN2O2 |
InChIKeyGPFWTAVHQKERKY-UHFFFAOYSA-N |
CAS Registry1449746-00-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 21 Jun 2021 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 21 Jun 2021 | |
Bile Duct Neoplasms | Phase 2 | CN | - | |
Breast Cancer | Phase 2 | CN | - | |
Pancreatic Cancer | Phase 2 | CN | - | |
Prostatic Cancer | Phase 2 | CN | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 16 Jul 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 16 Jul 2019 | |
Bladder Cancer | Phase 1 | CN | - | |
Glioma | Phase 1 | CN | - |